Novobiocin
Based on 14 publication(s) in Google Scholar
Novobiocin (Albamycin; Cathomycin) is an orally active aminocoumarin antibiotic (Antibiotic) and Hsp90 inhibitor. Novobiocin binds to the C-terminal nucleotide-binding site of Hsp90 and inhibits the function of this chaperone; Novobiocin competitively blocks ATP binding to GyrB, targets ParE in N. gonorrhoeae, inhibits human POLθ ATPase and the POLθ helicase-like domain in a non-ATP-competitive manner, and inhibits the catalytic activity of human TOP2A and TOP2B. Novobiocin inhibits MMEJ, blocks the recruitment of POLθ to DNA damage sites, induces ssDNA gap formation and apoptosis (Apoptosis), and exhibits synthetic lethality in HR-deficient tumors. Novobiocin can be used for research on equine piroplasmosis, gonorrhea, HR-deficient tumors, anthrax, melioidosis, and acute promyelocytic leukemia.
For research use only. We do not sell to patients.
- Purity : 97.88%
- CAS No.: 303-81-1
- Formula: C31H36N2O11
- Molecular Weight:612.62
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Novobiocin
More- Nat Methods. 2023 Sep;20(9):1388-1399. [Abstract]
- Blood. 2018 Jul 19;132(3):307-320. [Abstract]
- Adv Sci (Weinh). 2022 Dec;9(34):e2203088. [Abstract]
- Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
- Mol Ther. 2026 Jul 20:S1525-0016(26)00602-7.
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- Int J Mol Sci. 2019 Mar 5;20(5):1125. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Mol Pharm. 2022 Nov 7;19(11):4320-4332. [Abstract]
- Cancer Res Commun. 2024 Apr 9;4(4):1024-1040. [Abstract]
- J Med Virol. 2025 Oct;97(10):e70655. [Abstract]
- Surgery. 2024 Nov;176(5):1380-1387. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- bioRxiv. 2025 Sep 15.
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
WB
All Antibiotic Isoforms
MoreAll Parasite Isoforms
MoreAll DNA/RNA Synthesis Isoforms
MoreAll Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
[6]|
HSP90 |
topoisomerase II alpha 40 μM (IC50) |
topoisomerase II beta 600 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCC1937 | IC50 |
>80 μM
Compound: Novobiocin
|
Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
|
[PMID: 38375763] |
| HCT-116 | IC50 |
>80 μM
Compound: Novobiocin
|
Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
|
[PMID: 38375763] |
| HEK-293T | IC50 |
>100 μM
Compound: NB
|
Cytotoxicity against HEK293T cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against HEK293T cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 38107168] |
| HepG2 | IC50 |
>32 μg/mL
Compound: Novobiocin 1
|
Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-Glo assay
Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-Glo assay
|
[PMID: 30122228] |
| Huh-7 | CC50 |
1103.18 μg/mL
Compound: 33
|
Cytotoxicity against human HuH7 cells by MTT assay
Cytotoxicity against human HuH7 cells by MTT assay
|
[PMID: 31549836] |
| LNCaP | IC50 |
420 μM
Compound: NB
|
Antiproliferative activity against human LNCAP cells
Antiproliferative activity against human LNCAP cells
|
[PMID: 21129982] |
| MCF-10A | IC50 |
>80 μM
Compound: Novobiocin
|
Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
|
[PMID: 38375763] |
| MCF7 | GI50 |
260 μM
Compound: NVB
|
Growth inhibition of ER-positive human MCF7 cells after 72 hrs by MTT assay
Growth inhibition of ER-positive human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 24992077] |
| MCF7 | IC50 |
256 μM
Compound: 31
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 31663736] |
| MCF7 | IC50 |
260 μM
Compound: Novobiocin
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth
|
[PMID: 34952432] |
| MCF7 | IC50 |
260 μM
Compound: NVB
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation
|
[PMID: 24992077] |
| MCF7 | IC50 |
260 μM
Compound: NVB, novobiocin
|
Growth inhibition of MCF7 cells after 72 hrs by MTT assay
Growth inhibition of MCF7 cells after 72 hrs by MTT assay
|
[PMID: 17979263] |
| MCF7 | IC50 |
293.3 μM
Compound: Novobiocin
|
Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
|
[PMID: 27153346] |
| MCF7 | IC50 |
357 μM
Compound: 1a, NB
|
Cytotoxicity against ER-positive human MCF7 cells expressing low level of HER2 after 3 days by MTT assay
Cytotoxicity against ER-positive human MCF7 cells expressing low level of HER2 after 3 days by MTT assay
|
[PMID: 23859777] |
| MCF7 | IC50 |
481.3 μM
Compound: novobiocin
|
Antiproliferative activity against human MCF7 cells expressing ER
Antiproliferative activity against human MCF7 cells expressing ER
|
[PMID: 20570149] |
| MCF7 | IC50 |
85.1 μM
Compound: Novobiocin
|
Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining
Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining
|
[PMID: 19932960] |
| MDA-MB-436 | IC50 |
24.3 μM
Compound: Novobiocin
|
Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
|
[PMID: 38375763] |
| MDA-MB-468 | IC50 |
338.4 μM
Compound: Novobiocin
|
Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
|
[PMID: 27153346] |
| MDCK | IC50 |
104 μM
Compound: Novobiocin
|
Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay
Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay
|
[PMID: 19932960] |
| Sf9 | IC50 |
210 nM
Compound: 1
|
Inhibition of Escherichia coli His6-tagged ParC/ParE expressed in baculovirus-infected Sf9 cells by gel electrophoresis
Inhibition of Escherichia coli His6-tagged ParC/ParE expressed in baculovirus-infected Sf9 cells by gel electrophoresis
|
[PMID: 21235241] |
| SH-SY5Y | EC50 |
48.39 nM
Compound: novobiocin
|
Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release
Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release
|
[PMID: 19138859] |
| SK-BR-3 | EC50 |
700 μM
Compound: 1
|
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
|
[PMID: 29720349] |
| SK-BR-3 | IC50 |
~ 700 μM
Compound: 1
|
Antiproliferative activity against human SK-BR-3 cells
Antiproliferative activity against human SK-BR-3 cells
|
[PMID: 38516588] |
| SK-BR-3 | IC50 |
350 μM
Compound: 1a, NB
|
Cytotoxicity against ER-negative human SKBR3 cells expressing high level of HER2 after 3 days by MTT assay
Cytotoxicity against ER-negative human SKBR3 cells expressing high level of HER2 after 3 days by MTT assay
|
[PMID: 23859777] |
| SK-BR-3 | IC50 |
474.7 μM
Compound: novobiocin
|
Antiproliferative activity against human ER deficient SKBR3 cells over expressing HER2
Antiproliferative activity against human ER deficient SKBR3 cells over expressing HER2
|
[PMID: 20570149] |
| SK-BR-3 | IC50 |
700 mM
Compound: 1
|
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
|
[PMID: 24953820] |
| SK-BR-3 | IC50 |
700 μM
Compound: 1
|
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay
|
[PMID: 19932969] |
| SK-BR-3 | IC50 |
700 μM
Compound: 1
|
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay
|
[PMID: 24900777] |
| SK-BR-3 | IC50 |
700 μM
Compound: 1
|
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
|
[PMID: 25699150] |
| SK-BR-3 | IC50 |
700 μM
Compound: 5
|
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay
|
[PMID: 25462258] |
| SK-BR-3 | IC50 |
700 μM
Compound: Novobiocin
|
Antiproliferative activity against human SKBR3 cells expressing HER2 after 72 hrs by MTS/PMS assay
Antiproliferative activity against human SKBR3 cells expressing HER2 after 72 hrs by MTS/PMS assay
|
[PMID: 21553822] |
| SK-BR-3 | IC50 |
700 μM
Compound: Novobiocin
|
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
|
[PMID: 23234644] |
| SK-BR-3 | IC50 |
700 μM
Compound: Novobiocin
|
Antiproliferative activity against human SKBR3 cells
Antiproliferative activity against human SKBR3 cells
|
[PMID: 23606927] |
| SK-BR-3 | IC50 |
700 μM
Compound: Novobiocin
|
Cytotoxicity against human SKBR3 cells by MTS assay
Cytotoxicity against human SKBR3 cells by MTS assay
|
[PMID: 26745854] |
| SK-BR-3 | IC50 |
700 μM
Compound: Novobiocin
|
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay
Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay
|
[PMID: 30048133] |
| SK-BR-3 | IC50 |
700 μM
Compound: Novobiocin
|
Inhibition of human SKBR3 cell proliferation
Inhibition of human SKBR3 cell proliferation
|
10.1039/C0MD00063A |
| SK-OV-3 | IC50 |
>80 μM
Compound: Novobiocin
|
Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
|
[PMID: 38375763] |
| SW48 | IC50 |
>80 μM
Compound: Novobiocin
|
Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
|
[PMID: 38375763] |
| TERT-RPE1 | IC50 |
358.4 μM
Compound: 24; NVB
|
Antiproliferative activity against P53 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay
Antiproliferative activity against P53 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay
|
[PMID: 37134182] |
| TERT-RPE1 | IC50 |
86 μM
Compound: 24; NVB
|
Antiproliferative activity against BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay
Antiproliferative activity against BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay
|
[PMID: 37134182] |
| TERT-RPE1 | IC50 |
97.24 μM
Compound: 24; NVB
|
Antiproliferative activity against P53 and BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay
Antiproliferative activity against P53 and BRCA1 knockout human RPE-1 cells assessed as inhibition of cell growth by CellTiter-Glo assay
|
[PMID: 37134182] |
| Vero | CC50 |
850.5 μg/mL
Compound: 33
|
Cytotoxicity against African green monkey Vero cells by MTT assay
Cytotoxicity against African green monkey Vero cells by MTT assay
|
[PMID: 31549836] |
| Vero | EC50 |
15.21 μg/mL
Compound: 33
|
Inhibition of NS2B-NS3 protease in Zika virus Puerto Rico/PRVABC5 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by RT-PCR method
Inhibition of NS2B-NS3 protease in Zika virus Puerto Rico/PRVABC5 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by RT-PCR method
|
[PMID: 31549836] |
In Vitro
Novobiocin synergizes with Olaparib (HY-10162) in HR-deficient TOV21G + EV cells, reducing the IC50 of Olaparib by more than 40-fold[3].
Novobiocin (1-600 μM; 72 h) reduces proliferation in HL-60 cells starting from 60 μM after 72 h and does not attenuate the antiproliferative activity of Daunorubicin (19 nM)[6].
Novobiocin (serial dilution; 1 day) exhibits MIC values ranging from 0.25 to 8 μg mL-1 against N. gonorrhoeae DSM9188 and its genetically modified strains, in which the amino acid residues corresponding to Ile76 in ParE and Met82 in GyrB significantly affect Novobiocin sensitivity[2].
Novobiocin exhibits low in vitro effective concentrations against both Bacillus anthracis and Burkholderia pseudomallei[5].
Novobiocin (1-2000 μM; 90 min) exhibits very low hemolytic activity against horse erythrocytes, with a CC50 of 261.97 mM and an SSI of 1587, indicating that it is safe for host erythrocytes[1].
Novobiocin (30 min) directly binds to and stabilizes the POLθ ATPase domain in a dose-dependent manner[3].
Novobiocin (24 h) inhibits MMEJ repair but not HR repair in U2OS cells[3].
Novobiocin (50-100 μM; 24 h) increases IR-induced RAD51 and γH2AX foci formation in U2OS cells[3].
Novobiocin (12-14 days) selectively reduces the viability of BRCA1-/- and BRCA2-/- RPE1 cells compared with isogenic WT cells[3].
Novobiocin induces chromosomal aberrations and radial chromosomes in BRCA1-/- RPE1 cells[3].
Novobiocin is cytotoxic to multiple PARPi-resistant clones derived from RPE1-BRCA1-/- cells[3].
Novobiocin (120 nM-1 mM; preincubation for 1 h, reaction for 2 h) is a non-ATP-competitive inhibitor of Polθ-ATPase activity[4].
Novobiocin (4 mM; 30 min) binds to an allosteric site in the Polθ-ATPase domain, affecting ATP hydrolysis and stabilizing the domain core[4].
Novobiocin (500 μM; 30 min) stabilizes the Polθ-ATPase domain[4].
Novobiocin (500 μM; 1 h) promotes tetramerization of the Polθ-ATPase domain[4].
Novobiocin (50-200 μM; 24 h) blocks the binding of intracellular Polθ to ssDNA in a dose-dependent manner[4].
Novobiocin (200 μM; 2 h) exposure leads to the accumulation of ssDNA gaps in RPE1 TP53-/- BRCA1-/- cells[4].
Novobiocin (30 min) is a preferential TOP2A inhibitor in the recombinant human kDNA decatenation assay, with an IC50 of 40 μM for TOP2A and 600 μM for TOP2B[6].
Novobiocin (1-100 μM; 24 h) shows only a trend toward decreased TOP2 immunoreactivity in primary neonatal rat cardiomyocytes[6].
Novobiocin (100 μM; pretreatment for 30 min; co-exposure with 1.2 μM Daunorubicin for 90 min) reduces Daunorubicin-induced γH2AX accumulation by 48% in neonatal rat primary cardiomyocytes[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Theileria equi and Babesia caballi parasitized horse red blood cells (RBCs)
-
Concentration:1, 5, 10, 20, 50, 100, 200 μM (T. equi); 10, 20, 50, 100, 200 μM (B. caballi)
-
Incubation Time:96 h
-
Result:Inhibited the in vitro growth of Theileria equi with an IC50 of 165 μM.
Inhibited the in vitro growth of Babesia caballi with an IC50 of 84.85 μM.
Showed significant growth inhibition of T. equi at 100 μM and 200 μM at 24 h and 48 h.
Showed significant growth inhibition of T. equi at ≥ 20 μM at 72 h and 96 h.
Showed significant growth inhibition of B. caballi at 100 and 200 μM at 24, 48, 72, and 96 h.
Caused parasite death at 100 μM and 200 μM after 96 h.
Failed to inhibit growth at 1-50 μM (T. equi) and 10-50 μM (B. caballi) in viability studies.
Induced dot-shaped/distorted nuclear material at 100 and 200 μM after 96 h.
Showed no recrudescence at 100 and 200 μM in viability testing.
-
Cell Line:Equine peripheral blood mononuclear cells (PBMCs)
-
Concentration:1, 5, 10, 25, 50, 100, 1000, 2000 μM
-
Incubation Time:24 h
-
Result:Showed less than 10% cytotoxicity at 1000 μM.
Exhibited a CC50 of 11.63 mM.
Demonstrated a specific selective index (SSI) of 70.47.
-
Cell Line:U2OS POLQ knockout cells expressing Myc-tagged Polθ
-
Concentration:50, 100, 200 μM
-
Incubation Time:24 h
-
Result:Reduced Polθ recruitment to ssDNA in cells in a dose-dependent manner.
Blocked 96% of Polθ from being recruited to damage sites at the highest dose of 200 μM.
-
Cell Line:HL-60 human acute promyelocytic leukaemia cells
-
Concentration:1, 10, 30, 60, 100, 300, 600 μM
-
Incubation Time:72 h
-
Result:Produced concentration-dependent antiproliferative effects, with the lowest reported effective concentration at 60 μM.
When co-administered with 19 nM Daunorubicin, did not attenuate Daunorubicin antiproliferative activity; at higher concentrations tended to enhance cytotoxicity.
In Vivo
Novobiocin (100 mg/kg; i.p.; twice daily; 4 weeks) specifically inhibits the growth of FANCF-deficient HR-defective tumors in vivo[3].
Novobiocin (75 mg/kg; i.p.; twice daily; 4 weeks) as a single agent induces tumor regression, and in combination with Olaparib achieves complete tumor regression in the HR-deficient DF83 PDX model[3].
Novobiocin (75 mg/kg; i.p.; twice daily; 4 weeks) significantly reduces tumor growth in the PARPi (HY-156982)-resistant DF59 PDX model, indicating that no cross-resistance exists between PARP inhibition and Novobiocin[3].
Novobiocin (2.5 mg; i.p.; 2-5 doses) significantly prolongs the time to death in the highly lethal inhalational anthrax model in A/J mice (up to 8.3 days with the 4-dose regimen), but does not significantly improve overall survival[5].
Novobiocin (2.5 mg; i.p.; 4 doses; 7 days) provides 70% protection against lethal aerosol B. pseudomallei infection in BALB/c mice, and bacterial burden is typically undetectable in tissues of surviving mice[5].
Novobiocin (2.5 mg; i.p.; 3 doses) significantly synergizes with live attenuated vaccine, improving survival (80% at day 21) and prolonging time to death in a lethal aerosol B. pseudomallei model[5].
Novobiocin (75 mg/kg; i.p.; twice daily; 4 weeks) does not inhibit tumor growth in the HR-proficient DF149 PDX model, which is associated with low POLθ expression[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice (strain not specified)[1]
-
Dosage:5, 10, 20, 50, and 100 mg/kg
-
Administration:i.p.; single dose
-
Result:Induced a significant rise in serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) in mice at 100 mg/kg at 24 h, which decreased to non-significant levels thereafter.
Showed non-significant differences in kidney biochemical markers (creatinine, blood urea nitrogen) and other parameters (bilirubin and total protein) at different time intervals.
Exhibited minimal diffuse cytoplasmic rarefaction and vacuolation in hepatocytes at 100 mg/kg.
Showed no adverse histopathological changes in any organ at other doses.
Identified 50 mg/kg as the No Observed Adverse Effect Level (NOAEL).
-
Animal Model:FVB/129P2 (female, at least 6 weeks old, K14-Cre-Brca1f/f;Trp53f/f GEMM tumor transplanted into mammary fat pad)[3]
-
Dosage:100 mg/kg
-
Administration:i.p.; twice a day; 35 days
-
Result:Significantly suppressed tumor growth after 7 days of treatment and beyond.
Prolonged overall survival by 3-fold compared to vehicle, with median survival times of 29 and 10 days for treated and vehicle groups, respectively.
-
Animal Model:NU(NCr)-Foxn1nu athymic nude (female)[3]
-
Dosage:100 mg/kg
-
Administration:i.p.; twice a day; 4 weeks
-
Result:Specifically impaired the growth of FANCF-deficient tumors, with no effect on FANCF-complemented tumors.
Strongly induced RAD51 foci in the treated tumors.
-
Animal Model:NSG (female, 8 weeks old)[3]
-
Dosage:75 mg/kg
-
Administration:i.p.; twice daily; 4 weeks
-
Result:Led to tumor regression as a single agent, while tumors in vehicle-treated mice showed exponential growth.
Achieved complete tumor regression in combination with olaparib, with few tumor cells detectable via BLI on day 28.\nSubstantially reduced tumor growth as monotherapy.
In combination with Olaparib, further inhibited tumor growth with regression in the first two weeks.
Exhibited higher levels of phospho-RPA32 compared to vehicle-treated samples.
Exhibited a strong increase in RAD51 staining when treated alone or in combination with olaparib.\nDid not inhibit tumor growth in the HR-proficient DF149 PDX model.
-
Animal Model:A/J mice[5]
-
Dosage:5 mg; 1.25 mg; 2.5 mg
-
Administration:i.p.; 1, 2, or 3 doses
-
Result:Administered 5 mg once, achieving 60% protection.
Administered 5 mg in 2 or 3 doses, resulting in 100% lethality.
Administered 1.25 mg in 3 doses, protecting 10% of mice.
Administered 1.25 mg in 2 or 3 doses, extending time-to-mortality compared to PBS control.
Administered 2.5 mg in 3 doses, protecting 90% of mice.
-
Animal Model:BALB/c mice[5]
-
Dosage:1.25 mg; 2.5 mg
-
Administration:i.p.; 1, 2, or 3 doses
-
Result:Administered 1.25 mg or 2.5 mg in 1, 2, or 3 doses, achieving 70-90% protection except for a single 1.25 mg dose.
Administered 1.25 mg in 3 doses, achieving 90% protection.
Extended time-to-mortality in all treatment groups compared to PBS control.
Resulted in no detectable bacterial burden in spleens of most survivors.
-
Animal Model:A/J mice[5]
-
Dosage:2.5 mg
-
Administration:i.p.; 2, 3, 4, or 5 doses
-
Result:Administered 2.5 mg in 2 doses, resulting in a time-to-mortality of 5.8 days.
Administered 2.5 mg in 3 doses, resulting in a time-to-mortality of 6.7 days.
Administered 2.5 mg in 5 doses, resulting in a time-to-mortality of 6.9 days.
Administered 2.5 mg in 4 doses over 7 days, resulting in a time-to-mortality of 8.3 days.
Did not significantly improve overall survival rates by day 21.
-
Animal Model:BALB/c mice[5]
-
Dosage:2.5 mg
-
Administration:i.p.; 2, 3, 4, or 5 doses
-
Result:Administered 2.5 mg in 4 doses over 7 days, protecting 70% of mice.
Administered 2.5 mg in 5 doses over 3 days, protecting 60% of mice.
Administered 2.5 mg in 2 doses, protecting 22% of mice.
Administered 2.5 mg in 3 doses, protecting 20% of mice.
Resulted in no detectable bacteria in lung or spleen tissues of any survivors, except for one mouse in the 3-dose group with a bacterial burden of approximately 1.2 × 108 CFU/g in the spleen.
-
Animal Model:BALB/c mice (vaccinated)[5]
-
Dosage:2.5 mg
-
Administration:i.p.; 3 doses
-
Result:Achieved 80% survival at day 21.
Resulted in a geometric mean time-to-mortality of 35.1 days.
Yielded a synergy score of 3.15.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 303-81-1
-
Appearance Solid
-
Molecular Weight 612.62
-
Formula C31H36N2O11
-
Color White to off-white
-
SMILES
CC1=C(O2)C(C(O)=C(NC(C3=CC(C/C=C(C)/C)=C(O)C=C3)=O)C2=O)=CC=C1O[C@H]4[C@@H]([C@@H]([C@@H](OC)C(C)(C)O4)OC(N)=O)O
-
Synonyms
Albamycin; Cathomycin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Nat Methods
2023 Sep;20(9):1388-1399. PMID: 37474806
Novobiocin purchased from MedChemExpress. Usage Cited in: Nat Methods. 2023 Sep;20(9):1388-1399. [Abstract]
Editing efficiencies of the VCAN target using Cas9D10A double nicking in H9 hESCs carrying the K3753R mutation and additional small molecules to inhibit the MMEJ repair proteins Polϴ, PARP or Ligase I/III: Novobiocin.
-
Blood
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. [Abstract]2018 Jul 19;132(3):307-320. PMID: 29724897
Novobiocin purchased from MedChemExpress. Usage Cited in: Blood. 2018 Jul 19;132(3):307-320. [Abstract]
K562, KCL22 and HL60 are treated with the indicated (cytotoxic) concentration of Amidopyrine (AX), Novobiocin (NB) and AUY922 for 48h and later protein lysates are subjected to immunoblot analysis.
-
Adv Sci (Weinh)
SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. [Abstract]2022 Dec;9(34):e2203088. PMID: 36257906 -
Cell Rep Med
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]2024 Jun 18;5(6):101592. PMID: 38843841 -
-
-
Int J Mol Sci
Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma. [Abstract]2019 Mar 5;20(5):1125. PMID: 30841620
Novobiocin purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2019 Mar 5;20(5):1125. [Abstract]
Cell viability assay to analyze the impact of Probenecid and Novobiocin treatments on resistance.
-
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Mol Pharm
2022 Nov 7;19(11):4320-4332. PMID: 36269563 -
Cancer Res Commun
Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. [Abstract]2024 Apr 9;4(4):1024-1040. PMID: 38592451 -
J Med Virol
Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]2025 Oct;97(10):e70655. PMID: 41117261
Novobiocin purchased from MedChemExpress. Usage Cited in: J Med Virol. 2025 Oct;97(10):e70655. [Abstract]
Novobiocin also reduced NP expression at 25 μM, with mean fluorescence intensities significantly lower than those of the untreated control.
Novobiocin purchased from MedChemExpress. Usage Cited in: J Med Virol. 2025 Oct;97(10):e70655. [Abstract]
Cytoxicity and inhibition of Novobiocin, EC50 = 25.12 μM.
-
Surgery
Overexpression of human DNA polymerase theta is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancers. [Abstract]2024 Nov;176(5):1380-1387. PMID: 38897886 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (163.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (8.16 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (8.16 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (312 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[2]. Ishizaki Y, Hayashi C, Matoba K, Igarashi M. Novobiocin primarily targets ParE in Neisseria gonorrhoeae. J Antibiot (Tokyo). 2025 Feb;78(3):159-165. [Content Brief]
[3]. Zhou J, et al. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nature cancer. 2021 Jun;2(6):598-610. [Content Brief]
[4]. Syed A, et al. Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity. Nucleic Acids Res. 2023 Oct 13;51(18):9920-9937. [Content Brief]
[5]. Klimko CP, et al. Efficacy of Treatment with the Antibiotic Novobiocin against Infection with Bacillus anthracis or Burkholderia pseudomallei. Antibiotics (Basel). 2022 Nov 23;11(12):1685. [Content Brief]
[6]. Kubeš J, et al. Pharmacological correlates of topoisomerase II-directed protection against anthracycline-induced DNA damage and cardiotoxicity: a comparative evaluation of catalytic topoisomerase II inhibitors. Archives of toxicology. 2026 Oct 23. [Content Brief]
[7]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews. Cancer. 2009 May;9(5):338-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6323 mL | 8.1617 mL | 16.3233 mL | 40.8083 mL |
| 5 mM | 0.3265 mL | 1.6323 mL | 3.2647 mL | 8.1617 mL | |
| 10 mM | 0.1632 mL | 0.8162 mL | 1.6323 mL | 4.0808 mL | |
| 15 mM | 0.1088 mL | 0.5441 mL | 1.0882 mL | 2.7206 mL | |
| 20 mM | 0.0816 mL | 0.4081 mL | 0.8162 mL | 2.0404 mL | |
| 25 mM | 0.0653 mL | 0.3265 mL | 0.6529 mL | 1.6323 mL | |
| 30 mM | 0.0544 mL | 0.2721 mL | 0.5441 mL | 1.3603 mL | |
| 40 mM | 0.0408 mL | 0.2040 mL | 0.4081 mL | 1.0202 mL | |
| 50 mM | 0.0326 mL | 0.1632 mL | 0.3265 mL | 0.8162 mL | |
| 60 mM | 0.0272 mL | 0.1360 mL | 0.2721 mL | 0.6801 mL | |
| 80 mM | 0.0204 mL | 0.1020 mL | 0.2040 mL | 0.5101 mL | |
| 100 mM | 0.0163 mL | 0.0816 mL | 0.1632 mL | 0.4081 mL |